Mar 12, 2026 17:21 JST

Source: Eisai

Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
Exploring Sleep with Pokemon!

TOKYO, Mar 12, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it is launching an initiative to raise public awareness of the importance of sleep in collaboration with the smartphone application “Pokémon Sleep”.

It is estimated that 12.4 million adults in Japan—equivalent to 11.8% of the adult population—experience insomnia and the resulting daytime functional impairments.1 According to the 2023 National Health and Nutrition Survey by the Ministry of Health, Labour and Welfare, the percentage of people aged 20 and older who feel they have sufficient rest through sleep has shown a gradual decline, highlighting a consistent downward trend for over a decade.2 The proportion of people who sleep less than six hours per night has also reached 38.5% among men and 43.6% among women.2

The feeling of insufficient rest has been linked to decreased daytime performance and an increased risk of lifestyle-related diseases, and securing adequate sleep in terms of both quality and quantity is essential for health promotion and maintenance across all age groups.3 Accordingly, the importance of educational activities aimed at disseminating accurate sleep knowledge is increasing.

This initiative is part of Eisai’s efforts to build an ecosystem in the sleep field, a key focus area for the company. By leveraging Eisai’s scientific expertise in sleep and the ability of “Pokémon Sleep” to “inspire action through fun”, the collaboration aims to create opportunities for all generations to reflect on their own sleep and daytime performance, and subsequently raise awareness of the importance of healthy sleep.

As the first step of this collaborative awareness initiative, Eisai will provide the picture book “Snorlax’s Dream” to medical institutions across Japan that are actively involved in sleep disorder consultation, primarily to those registered with “Sleep Consultation Navigator” information site powered by Eisai. The story is set in the world of “Pokémon Sleep”. Through an adventure in search of Snorlax, the Pokémon characters convey the “importance of getting sufficient sleep and staying healthy” and “tips for a good sleep” in an entertaining way to readers of all ages. By making the picture book available in the waiting areas of medical institutions, the initiative aims to encourage patients to reflect on their own sleep habits in an environment where they are more likely to be considering their physical condition and lifestyle. Additionally, under the collaboration with Pokémon Sleep, Eisai plans to expand its awareness activities by updating patient education leaflets and creating video content that promotes healthy sleep habits.

(Please note that all materials provided are intended for distribution to medical institutions in Japan.)

Eisai aims to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities not only through the development of therapeutic drugs, but also by building an ecosystem in collaboration with other industries. Together with “Pokémon Sleep,” Eisai will continue to create an environment where people of different generations can reflect on their sleep habits and achieve positive behavioral changes toward a healthy lifestyle. Through these efforts, Eisai will further contribute not only to individuals living with insomnia and their families but also to those who have concerns about their sleep.

About “Pokémon Sleep”

Pokémon Sleep, the sleep tracker app that turns sleep into entertainment, can be downloaded for free on the Apple App Store or Google Play Store. Learn more about Pokémon Sleep at PokemonSleep.net.

[Product Information]

Title: Pokémon Sleep

MSRP: Free to play *Features in-app purchases

Publisher: The Pokémon Company

Developer: SELECT BUTTON Inc.

Platforms: iOS/Android

Genre: Simulation

Mode: Single-player

Supported languages: Japanese, English, Spanish, French, German, Italian, Korean, Traditional Chinese *The "Spanish" supported by this software is European Spanish.

[Official website] https://www.pokemonsleep.net/en/

[App store] https://app.adjust.com/1xkxcsv1

Pokémon Sleep is developed by SELECT BUTTON inc.

The Pokémon Company was established to manage the Pokémon brand. Currently, the company develops and produces video games, which is where Pokémon originates, as well as trading card games, animated TV series and movies, merchandise, tie-up promotions, events, and the Pokémon Center, directly managed Pokémon shops.

About the Sleep Information Website Operated by Eisai 

Eisai provides basic knowledge about sleep and insomnia, self-checks for sleep, information about treatments and medications for insomnia, through "Sodan.e-Nemuri". Additionally, the website offers a wide range of content about sleep for those struggling with sleep issues, including the "Sleep Consultation Navigator" which helps users search for medical institutions that can provide advice and treatments for sleep disorders and insomnia. Please see https://e-nemuri.eisai.jp/ for details. (Japanese only)

References

1. Clinical Guideline for the Management and Treatment of Sleep Disorders, 3rd Edition (Japanese only)

2. The 2023 National Health and Nutrition Survey by the Ministry of Health, Labour and Welfare (Japanese only) https://www.mhlw.go.jp/content/10900000/001338334.pdf

3. Sleep Guide for Health Promotion 2023 - Ministry of Health, Labour and Welfare (Japanese only)

https://www.mhlw.go.jp/content/001305530.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
 
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
 
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
More Press release >>

Latest Press Release


More Latest Release >>